Table 3.

Combination of the rexinoid LG100268 and the HDAC inhibitor vorinostat for prevention of lung cancer

VorinostatLG100268Vorinostat 250 + LG268 40
Control250 mg/kg diet40 mg/kg diet
Tumor number, size, and burden
 Number of slides110484848
 Average number of tumors (% control)3.22 ± 0.15 (100%)3.25 ± 0.23 (101%)2.15 ± 0.22a (81%)1.65 ± 0.21a,b (51%)
 Average tumor size, mm3 (% control)0.3 ± 0.04 (100%)0.2 ± 0.015 (67%)0.12 ± 0.02a (40%)0.1 ± 0.01a,b (33%)
 Average tumor burden, mm3 (% control)0.95 ± 0.11 (100%)0.65 ± 0.07 (68%)0.27 ± 0.04a (28%)0.18 ± 0.03a,c (19%)
Tumor histopathology
 Number of tumors35415610379
 Total number of low-grade tumors (% total)14 (4%)13 (8%)11a (11%)18a,c (23%)
 Total number of medium-grade tumors (% total)139 (39%)48 (31%)56a (54%)45a,b (53%)
 Total number of high-grade tumors (% total)201 (57%)95 (61%)36 (35%)a,b19 (24%)a,b

NOTE: Female A/J mice were injected i.p. with two doses of vinyl carbamate (0.32 mg/mouse) 1 week apart. One week after the last treatment of carcinogen, mice were fed for 15 weeks with either control diet or drugs in diet at the indicated dose. Values represent mean ± SEM.

  • aP < 0.05 vs. control.

  • bP < 0.05 vs. vorinostat alone.

  • cP < 0.05 vs. vorinostat and LG268 alone.